Viruses, Vol. 16, Pages 682: Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

Viruses, Vol. 16, Pages 682: Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) Viruses doi: 10.3390/v16050682 Authors: Maria Giovanna Quaranta Luisa Cavalletto Francesco Paolo Russo Vincenza Calvaruso Luigina Ferrigno Alberto Zanetto Benedetta Mattioli Roberta D’Ambrosio Valentina Panetta Giuseppina Brancaccio Giovanni Raimondo Maurizia Rossana Brunetto Anna Linda Zignego Carmine Coppola Andrea Iannone Elisa Biliotti Elena Rosselli Del Turco Marco Massari Anna Licata Francesco Barbaro Marcello Persico Filomena Morisco Maurizio Pompili Federica Cerini Massimo Puoti Teresa Santantonio Antonio Craxì Loreta A. Kondili Liliana Chemello Investigators on behalf of PITER Collaborating Investigators on behalf of PITER Collaborating Investigators The treatment of hepatitis C virus (HCV) with direct-acting antivirals (DAA) leads to high sustained virological response (SVR) rates, but hepatocellular carcinoma (HCC) risk persists in people with advanced liver disease even after SVR. We weighted the HCC risk in people with cirrhosis achieving HCV eradication through DAA treatment and compared it with untreated participants in the multicenter prospective Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. Propensity matching with inverse probability weighting was used to compare DAA-treated and un...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research